Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BE CAR-33 in Relapsed Pediatric AML
NCT05942599Phase 1Active, not recruiting
- Sponsor
- Great Ormond Street Hospital
- Start
- Jul 2023
- Primary completion
- Jun 2026
- Modality
- CRISPR-Cas9, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BE CAR-33 in acute myeloid leukemia (AML), sponsored by Great Ormond Street Hospital. Primary endpoint: Adverse Events at 1 year. Started Jul 2023; status: active, not recruiting.
02
Drugs
BE CAR-33
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05942599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942599.